Kodiak Sciences (KOD) closed at $85.75 on October 16, 2026, down 2.7% from the previous close, on volume of 1,087,798 shares (30-day average 2,799,944).
Data as of October 16, 2026.
16-Oct-2026
Market Chameleon (Wed, 7-Oct 7:42 AM ET)
Kodiak Sciences to Present Clinical Data Across All Three Late-Stage Programs at AAO 2026
PRNewswire (Wed, 7-Oct 7:00 AM ET)
4 Explosive Stories Enter the Investor Spotlight
Globe Newswire (Mon, 28-Sep 11:51 AM ET)
PRNewswire (Fri, 25-Sep 6:02 PM ET)
Kodiak Sciences Announces Recent Business Highlights and Second Quarter 2026 Financial Results
PRNewswire (Thu, 13-Aug 4:00 PM ET)
PRNewswire (Mon, 10-Aug 4:44 PM ET)
PRNewswire (Thu, 6-Aug 7:00 AM ET)
Market Chameleon (Wed, 1-Apr 5:47 AM ET)
Market Chameleon (Fri, 27-Mar 6:30 AM ET)
Kodiak Sciences Inc has developed a new technology platform, the Antibody Biopolymer Conjugate (ABC) platform, for retinal medicines. Its investigational medicine, tarcocimab tedromer (Zenkuda or tarcocimab), is an anti-VEGF therapy built on Kodiak's proprietary ABC platform. Another investigational medicine, KSI-501, is an anti-interleukin 6, or IL-6, VEGF-trap bispecific therapy built on the ABC platform and is being developed for high-prevalence retinal vascular diseases and intended to address the unmet needs of extended durability and targeting disease biology beyond VEGF for differentiated efficacy. Its third investigational medicine, KSI-101, is a high-strength (100 mg/mL) bispecific protein targeting IL-6 and VEGF.
Kodiak Sciences trades on the NASDAQ stock market under the symbol KOD.
As of October 16, 2026, KOD stock price declined to $85.75 with 1,087,798 million shares trading.
KOD has a beta of 1.40, meaning it tends to be more sensitive to market movements. KOD has a correlation of 0.02 to the broad based SPY ETF.
KOD has a market cap of $5.39 billion. This is considered a Mid Cap stock.
In the last 3 years, KOD traded as high as $104.00 and as low as $1.37.
The top ETF exchange traded funds that KOD belongs to (by Net Assets): VTI, XBI, IWM, VXF, IBB.
KOD has outperformed the market in the last year with a return of +474.7%, while the SPY ETF gained +16.7%. In the last 3 month period, KOD beat the market returning +107.9%, while SPY returned +1.9%. However, in the most recent 2 weeks KOD has underperformed the stock market by returning -9.2%, while SPY returned -0.8%.
KOD support price is $82.58 and resistance is $93.66 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that KOD shares will trade within this expected range on the day.
